MELBOURNE, Australia and SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE)-- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...
Furthermore, the study – led by investigators at Vanderbilt University Medical Center in collaboration with Alterity Therapeutics’ (ASX:ATH) – found QSM can distinguish MSA from Parkinson’s disease ...
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results